What are the diagnostic criteria for primary biliary cholangitis in a middle‑aged woman presenting with a cholestatic pattern of liver enzymes?

Primary Biliary Cholangitis Diagnosis

A diagnosis of PBC can be made confidently with the combination of elevated alkaline phosphatase (AP) for at least 6 months and positive antimitochondrial antibodies (AMA) at a titer ≥1:40—liver biopsy is not required when both criteria are met. 1

Diagnostic Algorithm

Step 1: Initial Biochemical Assessment

• Cholestatic enzyme pattern: Elevated alkaline phosphatase (AP) and gamma-glutamyl transferase (GGT) are the hallmark findings 1
• Aminotransferases (ALT, AST) may be elevated but are not diagnostic
• Conjugated bilirubin elevation indicates more advanced disease
• Elevated IgM is typical but not required for diagnosis 1

Step 2: Exclude Extrahepatic Obstruction

• Ultrasound is mandatory as the first-line imaging to rule out biliary obstruction 1
• If ultrasound is inconclusive and clinical suspicion for obstruction remains, proceed to MRCP rather than ERCP to avoid procedural complications 1

Step 3: Serological Testing

AMA testing is mandatory in all adults with chronic intrahepatic cholestasis 1:

• AMA ≥1:40 has >90% sensitivity and >95% specificity for PBC 1
• Anti-AMA-M2 (anti-PDC-E2) by immunoenzymatic assay is an acceptable alternative with higher sensitivity and specificity 1

If AMA is negative, test for PBC-specific antinuclear antibodies:

• Anti-Sp100 and anti-gp210 have >95% specificity for PBC but low sensitivity 1
• These can establish the diagnosis in AMA-negative cases 2
• Emerging markers (anti-hexokinase 1, anti-KLHL12) may help identify rare seronegative cases 2

Step 4: When Liver Biopsy is Indicated

Biopsy is NOT required when cholestatic enzymes + positive AMA are present 1. However, biopsy should be performed in these situations:

• AMA-negative patients with unexplained cholestasis 1, 3
• Disproportionately elevated transaminases or IgG suggesting overlap syndrome 1
• Need for disease staging and activity assessment 1

Biopsy requirements: Must contain ≥10 portal fields due to sampling variability 1. The "florid duct lesion" (focal duct obliteration with granulomas) is nearly pathognomonic when present 1.

Step 5: Additional Imaging if Diagnosis Remains Unclear

• MRCP should be performed in AMA-negative patients with persistent unexplained cholestasis to exclude small duct PSC and other biliary pathology 1

Key Diagnostic Criteria Summary

Two of three criteria establish the diagnosis 1, 4, 5:

1. Cholestatic liver enzymes (elevated AP for ≥6 months)
2. Positive AMA ≥1:40 or PBC-specific ANA (anti-Sp100, anti-gp210)
3. Compatible liver histology (when biopsy performed)

Common Pitfalls to Avoid

• Do not delay diagnosis waiting for symptoms—most patients are asymptomatic at diagnosis 1
• Do not perform ERCP for diagnostic purposes when MRCP is available, given ERCP's 2% bleeding risk, 1% cholangitis risk, and 0.4% mortality 1
• Do not dismiss PBC based on negative AMA alone—5-10% of PBC patients are AMA-negative but may have PBC-specific ANAs 1, 2, 3
• Do not require liver biopsy when both cholestatic enzymes and positive AMA are present—this unnecessarily delays treatment 1, 4
• Monitor AMA-positive patients with normal liver enzymes annually, as they may develop biochemical cholestasis over time 1